Jove
Visualize
Contact Us

Related Experiment Videos

Experience with bisphosphonates in osteogenesis imperfecta.

Francis H Glorieux1

  • 1Genetics Unit, Shriners Hospital for Children and McGill University, Montreal, Quebec, Canada. glorieux@shriners.mcgill.ca

Pediatrics
|March 3, 2007
PubMed
Summary

Pamidronate therapy significantly improves bone density and reduces fractures in osteogenesis imperfecta patients. This bisphosphonate treatment enhances mobility and function, becoming the standard of care for moderate-to-severe cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone microstructural and strength changes over 1 year in children with osteogenesis imperfecta are comparable to age- and sex-matched healthy controls.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2024
Same author

Bone matrix properties in adults with osteogenesis imperfecta are not adversely affected by setrusumab-a sclerostin neutralizing antibody.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2024
Same author

Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period.

JBMR plus·2024
Same author

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.

The Journal of clinical endocrinology and metabolism·2023
Same author

Standardized growth charts for children with osteogenesis imperfecta.

Pediatric research·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Orthopedics
  • Genetics
  • Pharmacology

Background:

  • Osteogenesis imperfecta (OI) is a genetic disorder characterized by reduced bone mass and frequent fractures.
  • Historically, medical management for OI was limited, focusing on supportive care to maximize mobility and function.

Purpose of the Study:

  • To evaluate the impact of bisphosphonate therapy, specifically pamidronate, on the medical management of osteogenesis imperfecta.
  • To assess the benefits and potential risks of pamidronate in patients with moderate-to-severe OI.

Main Methods:

  • Review of cyclic intravenous pamidronate therapy in osteogenesis imperfecta patients.
  • Analysis of bone density, fracture rates, functional parameters, and histomorphometric changes.
  • Assessment of potential adverse effects on bone healing and remodeling.

Related Experiment Videos

Main Results:

  • Pamidronate therapy increases bone density and decreases fracture rates in OI patients.
  • Functional improvements include increased energy, reduced bone pain, and enhanced ambulation.
  • Histomorphometry shows reduced osteoclast activity, leading to increased cortical thickness and trabecular bone volume.

Conclusions:

  • Pamidronate therapy has become the standard of care for moderate-to-severe osteogenesis imperfecta, with benefits outweighing potential risks.
  • Further research is needed regarding optimal treatment duration and the necessity of pamidronate for mild OI cases.